Cooper Companies (COO) PT Raised to $100 at Oppenheimer
Oppenheimer analyst Steven Lichtman raised the price target on Cooper Companies (NASDAQ: COO) to $100.00 (from $90.00) while maintaining a Perform rating.
The analyst comments "COO's F1Q24 sales of $931.6M (+8% organic) were ahead of our/Street's ~$923.6/$916M ests, with Office/Surgical leading the beat versus our estimate including higher Cook acquisition contribution. MyDay daily SiHy led CVI with capacity expansion efforts supported meeting solid demand. Myopia management was slightly below on softer Ortho-K China performance. EPS of $0.85 beat our $0.79E (adjusted for 2/16 4:1 stock-split) including higher GM. FY24 sales guidance raised to 7–8% organic from 6–8% with increases in both CVI and CSI. CVI price increases remain above historical levels (price increase in F1Q). In CSI, double-digit Fertility growth continued to lead the way. SightGlass FDA approval now targeted in 2H25E as COO and its JV partner Essilor continue to work with FDA."